Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAVS Naphthalan in OLP and RAS
NCT02920658Phase 2Completed
- Start
- Dec 2010
- Primary completion
- Nov 2013
- Modality
- Hydrogel Systems, Transdermal Patches
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NAVS naphthalan in oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS). Primary endpoint: Reticulation, Erythema and Ulceration at 28 days. Started Dec 2010; status: completed.
02
Drugs
NAVS naphthalan
03
Conditions
oral lichen planus (OLP)recurrent aphthous stomatitis (RAS)
Beyond the preview
Go deeper on NCT02920658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02920658.